National Trends in the Use of Neoadjuvant Chemotherapy for Hormone Receptor-Negative Breast Cancer: A National Cancer Data Base Study

Abstract

In hormone receptor-negative breast cancer, chemotherapy was mostly administered adjuvantly, but neoadjuvant use increased over time and was more likely in younger patients and higher T- and N-stage disease. Node-positive patients treated with NAC were less likely to have pathologically positive nodes and more likely to have less extensive axillary surgery.

Present and changing trends in surgical modalities and neoadjuvant chemotherapy administration for female breast cancer in Beijing, China: A 10‐year (2006–2015) retrospective hospitalization summary report‐based study

“…The proportion of patients treated with NACT in Beijing continuously increased over the decade, particularly in patients with lymph node involvement. This is consistent with the results of a nationwide US study of 171 985 patients, which reported that an increasing number of patients received NACT, subsequently contributing to the increased application of BCS. This might partly explain why the proportion of patients who underwent BCS in the present study was higher than in previous research.…”

“…Neoadjuvant chemotherapy was developed as a new approach against breast cancer that involved less dissection and achieved better clinical outcomes. In our study, 22.92% of female patients received chemotherapy prior to surgery, slightly higher compared to 17.4–17.7% in the US, but lower than the 35.2% of patients in South Africa . The use of NACT is higher in younger than in older patients who do not commonly have contradictions, which is also consistent with the results of large studies conducted in Asia and the US .…”

“…In our study, 22.92% of female patients received chemotherapy prior to surgery, slightly higher compared to 17.4–17.7% in the US, but lower than the 35.2% of patients in South Africa . The use of NACT is higher in younger than in older patients who do not commonly have contradictions, which is also consistent with the results of large studies conducted in Asia and the US . In our study, the proportion of patients treated with NACT before RM (35.15%) and MRM (24.87%) was higher than BCS (22.02%), and patients with metastatic tumors (33.88%) most frequently receive NACT compared to other subgroups.…”

“…71 The use of NACT is higher in younger than in older patients who do not commonly have contradictions, which is also consistent with the results of large studies conducted in Asia and the US. 68,72,73 In our study, the proportion of patients treated with NACT before RM (35.15%) and MRM (24.87%) was higher than BCS (22.02%), and patients with metastatic tumors (33.88%) most frequently receive NACT compared to other subgroups. Studies have shown that NACT did convert mastectomy patients to candidates for BCS and reduced the number of dissected lymph nodes.…”

Does surgery or radiation provide the best overall survival in Ewing's sarcoma? A review of the National Cancer Data Base

“…The NCDB captures treatment and outcomes data for 70% of new cancer diagnoses in the United States, serving as a valuable resource for researchers as well as those interested in quality control . Similar investigations have utilized the NCDB to report on survival after various forms of treatment in many malignancies . However, the NCDB has not been previously utilized to investigate the overall survival associated with various methods of local control in patients with Ewing's sarcoma.…”